• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 24, 2015

View Archived Issues

Investors 'Cara' bout phase II uremic pruritus data, light up shares

Investors propelled shares of Cara Therapeutics Inc. (NASDAQ:CARA) to a one-year high Thursday after the company reported top-line results from the phase II trial of lead kappa opioid agonist CR845, which hit its primary endpoint in treating moderate to severe uremic pruritus (UP). Read More

Sutrovax raises $22M in series A financing for conjugate vaccines

Sutrovax Inc., a vaccine-focused spinout of Sutro Biopharma Inc., has completed a $22 million series A financing. Read More

With BPCIA dance optional, next moves up to biosimilar sponsors

Biosimilar sponsors are looking to put their best foot forward now that the Federal Circuit has agreed with a lower court that they don't have to dance to the tune of the Biologic Price Competition and Innovation Act's (BPCIA) intricate patent information exchange. Read More

Insights in pediatric disease prompt EMA to change waiver rules

LONDON - The EMA is making moves to increase the number of drugs approved for use in children, revoking eight of the 32 class waivers currently in force, which free companies of any obligation to develop products for pediatric use, and revising 15 others. Read More

Gene discovery clue to novel scoliosis targets

HONG KONG – The discovery by Japanese researchers of a single nucleotide polymorphism (SNP) in a gene linked to increased susceptibility to adolescent idiopathic scoliosis (AIS), could lead to the identification of new therapeutic targets for this common and currently incurable condition. Read More

Central American integration creating opportunities in biotech

BOGOTA, Colombia – Economic integration processes among Latin American countries are playing a key role in outlining regulatory standards for the life sciences industry. Read More

Financings

Gensight Biologics SA, of Paris, said it completed a series B preferred stock financing of about $36 million. New investors include Fidelity Management & Research Co., Jennison Associates, Sphera Global Healthcare Fund, Perceptive Advisors and Healthcap. Existing series A investors also participated in the round. Read More

Stock movers

Read More

In the clinic

Heron Therapeutics Inc., of Redwood City, Calif., said it started a second phase II trial of HTX-011, its Biochronomer-formulated long-acting formulation of local anesthetic bupivacaine in a fixed-dose combination with anti-inflammatory meloxicam for the prevention of postoperative pain. Read More

Other news to note

Omeros Corp., of Seattle, said it received FDA fast track designation for OMS721 for the treatment of patients with atypical hemolytic uremic syndrome (aHUS). Read More

Earnings

Celgene Corp., of Summit, N.J., reported net product sales of $2.254 billion for the second quarter, a 22 percent increase over the same period a year ago. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • 3D heart in chest

    At CRVBC 2025: Aging is circulating in your blood

    BioWorld Science
    All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, like waste products, toxins,...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe